Australia - English - Department of Health (Therapeutic Goods Administration)

lipa pharmaceuticals ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

star combo australia pty ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,sodium ascorbate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,sodium ascorbate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,sodium ascorbate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,sodium ascorbate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - calcium ascorbate dihydrate,citrus bioflavonoids extract,hesperidin,rutoside,sodium ascorbate,zinc oxide -

Australia - English - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - sodium ascorbate, quantity: 562.4 mg (equivalent: ascorbic acid, qty 500 mg); hesperidin, quantity: 5 mg; rutoside, quantity: 5 mg; zinc amino acid chelate, quantity: 40 mg (equivalent: zinc, qty 8 mg); citrus bioflavonoids extract, quantity: 50 mg; calcium ascorbate dihydrate, quantity: 605.3 mg (equivalent: ascorbic acid, qty 500 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; carnauba wax; hypromellose; croscarmellose sodium; macrogol 400; povidone; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; maintain/support bone health ; maintain/support blood capillary health ; maintain/support blood vessel health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support reproductive system health ; maintain/support prostate health ; maintain/support semen health ; maintain/support sperm health ; maintain/support sperm motility ; maintain/support skin health ; maintain/support wound healing

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a c

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d